Preclinical Evaluation of a Targeted Alpha-Emitting Radionuclide in Radiotheraphy of Breast Cancer
Abstract
The research effort is directed at evaluation of the alpha-emitting radionuclide, Bi-2l3 targeted to a metastatic breast cancer model (subrenal capsules) in an antibody-targeted protocol called "pretargeting". In the studies, biotinylated anti-breast cancer antibody, huBrE-3 was to be used as a pretargeting agent. However, the antibody has not been provided to us (as previously promised). A substantial amount of work has been conducted to find an alternative antibody for use in the studies. The antibodies, L6 and NR-LU-lO are being evaluated as alternatives. Subrenal capsules of MCF-7 cells have been prepared, with a successful growth rate of 75%. The carrier for Bi-2l3 in the pretargeting protocols can be either modified streptavidin or a biotin-chelate derivative. Three biotin derivatives containing the CHX (DTPA) chelate and one containing the DOTA chelate were synthesized for the study. The biotin-DOTA derivative labeled too slowly for use with Bi-2l3. Streptavidin has been conjugated with the CHX-A' chelate and succinylated to obtain low kidney concentrations. Biodistribution of the Bi-2l3 labeled succinylated CHX-A' -streptavidin vs the same material radioiodinated demonstrated that the Bi-2l3 label was very stable in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1999
- Accession Number
- ADA385390
Entities
People
- D. S. Wilbur
Organizations
- University of Washington